The synthesis, physico-chemical behavior, and in vitro intracellular degradation of new biodegradable graft, diblock or multiblock polymer carriers that were designed to deliver bioactive compounds by passive tumor targeting were investigated. The graft polymer carriers consisted of the N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer backbone grafted with a semitelechelic HPMA copolymer. The diblock polymer carriers were prepared by condensation of two semitelechelic HPMA copolymers. The multiblock polymer drug carrier was prepared by oxidative polycondensation of PEG-bis-cysteine. In all three carrier systems, the single polymers were linked via biodegradable disulfide bonds forming the graft, diblock or multiblock polymers. These polymers are potential polymer carriers for solid tumor-specific drug delivery with subsequent intracellular degradation to short polymer fragments that can be excreted by glomerular filtration. Prolonged blood circulation, accumulation in solid tumors, and drug release from these carriers have been reported. Here, degradation of the polymers in model buffer solutions mimicking intracellular environment as well as after incubation with EL4 T-cell lymphoma cancer cells were investigated. In both cases, degradation resulted in polymer fragments of molecular weight below the renal threshold.
Ulbrich, K., Etrych, T., Chytil, P., Jelínková, M. and Říhová, B. (2004). Antibody-targeted Polymer-Doxorubicin Conjugates with pH-controlled Activation, J. Drug Target. , 12: 477-489.
2.
Vicent, M.J. and Duncan, R. (2006). Polymer Conjugates: Nanosized Medicines for Treating Cancer, Trends Biotechnol., 24: 39-47.
3.
Garnett, M.C. (2001). Targeted Drug Conjugates: Principles and Progress, Adv. Drug Deliv. Rev., 53: 171-216.
4.
Haag, R. and Kratz, F. ( 2006). Polymer Therapeutics: Concepts and Applications, Angew . Chem. Int. Ed. Engl., 45: 1198-1215.
5.
Kopeček, J., Kopečková , P., Minko, T. and Lu , Z.R. (2000). HPMA Copolymer-Anticancer Drug Conjugates: Design, Activity, and Mechanism of Action, Eur. J. Pharm. Biopharm., 50: 61-81.
6.
Duncan, R. ( 2003). The Dawning Era of Polymer Therapeutics, Nat. Rev. Drug Discov., 2: 347-360.
7.
Pechar, M., Strohalm, J., Ulbrich, K. and Schacht, E.H. ( 1997). Biodegradable Drug Carriers Based on Poly(ethyleneglycol) Block Copolymers, Macromol. Chem. Phys., 198: 1009-1020.
8.
Braunová, A., Pechar, M., Laga, R. and Ulbrich, K. (2007). Hydrolytically and Reductively Degradable Poly(ethylene glycol)s, Macromol. Chem. Phys., 208: 2642-2653.
9.
Dvořák, M., Kopečková , P. and Kopeček, J. (1999). High-Molecular Weight HPMA Copolymer-Adriamycin Conjugates, J. Control. Release, 60: 321-332.
10.
Etrych, T., Mrkvan, T., Říhová, B. and Ulbrich, K. (2007). Star-shaped Immunoglobulin-containing HPMA-based Conjugates With Doxorubicin for Cancer Therapy, J. Control. Release, 122: 31-38.
11.
Maeda, H. ( 2001). The Enhanced Permeability and Retention (EPR) Effect in Tumor Vasculature: The Key Role of Tumor-Selective Macromolecular Drug Targeting, Adv. Enzyme Regul., 41: 189-207.
12.
Maeda, H. and Matsumura, Y. ( 1989). Tumoritropic and Lymphotropic Principles of Macromolecular Drugs, Crit. Rev. Ther. Drug Carrier Syst., 6: 193-210.
13.
Etrych, T., Chytil, P., Mrkvan, T., Šírová, M. , Říhová , B. and Ulbrich, K. (2008). Conjugates of Doxorubicin with Graft HPMA Copolymers for Passive Tumor Targeting , J. Control. Release, 132: 184-192.
14.
Shiah, J.B., Dvořák, M., Kopečková, P., Sun, Y., Peterson, C.M. and Kopeček, J. ( 2001). Biodistribution and Antitumor Efficacy of Long-Circulating N-(2-hydroxypropyl)methacrylamide Copolymer-Doxorubicin Conjugates in Nude Mice, Eur. J. Cancer, 37: 131-139.
15.
Mero, A., Schiavon, O., Pasut, G., Veronese, F.M., Emilitri, E. and Ferruti, P. ( 2009). A Biodegradable Polymeric Carrier Based on PEG for Drug Delivery, J. Bioact. Compat. Polym., 24: 220-234.
16.
Ulbrich, K. and Šubr, V. ( 2004). Polymeric Anticancer Drugs with pH-Controlled Activation , Adv. Drug Deliv. Rev., 56: 1023-1050.
17.
Říhová, B., Etrych, T., Pechar, M., Jelínková , M., Štastny, M., Hovorka, O. et al. (2001). Doxorubicin Bound to a HPMA Copolymer Carrier Through Hydrazone Bond is Effective also in a Cancer Cell Line With a Limited Content of Lysosomes, J. Control. Release, 74: 225-232.
18.
Etrych, T., Jelínková, M., Říhová, B. and Ulbrich, K. (2001). New HPMA Copolymers Containing Doxorubicin Bound via pH-Sensitive Linkage: Synthesis and Preliminary In Vitro and In Vivo Biological Properties, J. Control. Release, 73: 89-102.
19.
Pechar, M., Braunová, A., Ulbrich, K., Jelínková, M. and Říhová, B. (2008). Poly(Ethylene Glycol)-Doxorubicin Conjugates with pH-controlled Activation, J. Bioact. Compat. Polym., 20: 319-341.
20.
Harmon, A.M. and Uhrich, K.E. (2009). In Vitro Evaluation of Amphiphilic Macromolecular Nanocarriers for Systemic Drug Delivery, J. Bioact. Compat. Polym., 24: 185-197.
21.
Li, J.T. , Carlsson, J., Lin, J.N. and Caldwell, J.D. (1996). Chemical Modification of Surface Active Poly(Ethylene Oxide)-Poly(Propylene Oxide) Triblock Copolymers , Bioconjugate Chem., 7: 592-599.
22.
Ebright, Y.B. , Chen, Y., Pendergrast, P.S. and Ebright, R.H. (1992). Incorporation of an EDTA-Metal Complex at a Rationally Selected Site Within a Protein - Application to EDTA-Iron DNA Affinity Cleaving with Catabolite Gene Activator Protein (Cap) and Cro, Biochemistry (Moscow), 31: 10664-10670.
23.
Zalipsky, S., Seltzer, R. and Nho, K. ( 1991). Succinimidyl Carbonates of Polyethylene Glycol: Useful Reactive Polymers for Preparation of Protein Conjugates, In: Dunn, R.L. and Ottenbrite, R.M. (eds), Polymeric Drugs and Drug Delivery Systems, pp. 91-101, American Chemical Society, Washington DC.
24.
Ulbrich, K. , Šubr, V., Strohalm, J., Plocová , D., Jelínková, M. and Říhová, B. (2000). Polymeric Drugs Based on Conjugates of Synthetic and Natural Macromolecules I. Synthesis and Physico-chemical Characterisation, J. Control. Release, 64: 63-79.
25.
Etrych, T., Mrkvan, T., Chytil, P., Koňák, C., Říhová, B. and Ulbrich, K. (2008). N-(2-hydroxypropyl)methacrylamide-based Polymer Conjugates with pH-Controlled Activation of Doxorubicin. I. New Synthesis, Physicochemical Characterization and Preliminary Biological Evaluation, J. Appl. Polym. Sci., 109: 3050-3061.
26.
Šubr, V. and Ulbrich, K. (2006). Synthesis and Properties of New N-(2-hydroxypropyl)methacrylamide Copolymers Containing Thiazolidine-2-thione Reactive Groups, React. Funct. Polym., 66: 1525-1538.
27.
Šubr, V., Koňák , C., Laga, R. and Ulbrich, K. (2006). Coating of DNA/poly (L-lysine) Complexes by Covalent Attachment of Poly[N-(2-hydroxypropyl)-methacrylamide] , Biomacromolecules, 7: 122-130.
Grassetti, D.R. and Murray Jr, J.F. (1967). Determination of Sulfhydryl Groups with 2,2′- or 4,4′-Dithiodipyridine, Arch. Biochem. Biophys., 119: 41-50.
30.
Chan, W.C. and White, P.D. (eds), (2000). Fmoc Solid Phase Peptide Synthesis: A Practical Approach, Oxford University Press , Oxford.
31.
Steyger, P.S. , Baban, D.F., Brereton, M., Ulbrich, K. and Seymour, L.W. (1996). Intratumoral Distribution as a Determinant of Tumor Responsiveness to Therapy Using Polymer-Based Macromolecular Prodrugs, J. Control. Release, 39: 35-46.
32.
Noguchi, Y. , Wu, J., Duncan, R., Strohalm, J., Ulbrich, K., Akaike, T. et al. (1998). Early Phase Tumor Accumulation of Macromolecules: A Great Difference in Clearance Rate Between Tumor and Normal Tissue, Jpn. J. Cancer Res., 89: 307-314.
33.
Lammers, T. , Kissel, M., Kühnlein, R., Šubr, V., Etrych, T., Ulbrich, K. et al. (2005). Effect of Physicochemical Modification on Kinetics, Tissue Distribution and Tumor Targeting Potential of pHPMA, J. Control. Release, 110: 103-118.
34.
Kissel, M., Peschke, P., Šubr, V., Ulbrich, K., Schuhmacher, J., Debus, J. et al. (2001). Synthetic Macromolecular Drug Carriers: Biodistribution of Poly [(N-2-hydroxypropyl)methacrylamide] Copolymers and Their Accumulation in Solid Rat Tumors, PDA J. Pharm. Sci. Technol., 55: 191-201.
35.
Lammers, T. , Peschke, P., Kuhnlein, R., Šubr, V., Ulbrich, K., Debus, J. et al. (2007). Effect of Radiotherapy and Hyperthermia on the Tumor Accumulation of HPMA Copolymer-based Drug Delivery Systems, J. Control. Release, 117: 333-341.
36.
Saito, G., Swanson, J.A. and Lee, K.D. ( 2003). Drug Delivery Strategy Utilizing Conjugation via Reversible Disulfide Linkages: Role and Site of Cellular Reducing Activities, Adv. Drug Deliv. Rev., 55: 199-215.
37.
Meister, A. (1991). Glutathione Deficiency Produced by Inhibition of its Synthesis, and its Reversal; Applications in Research and Therapy, Pharmacol. Ther., 51: 155-194.
